42T.SI - The Trendlines Group Ltd.

SES - SES Delayed Price. Currency in SGD
0.0870
0.0000 (0.00%)
At close: 3:52PM SGT
Stock chart is not supported by your current browser
Previous Close0.0870
Open0.0870
Bid0.0870 x 0
Ask0.0880 x 0
Day's Range0.0870 - 0.0880
52 Week Range0.0760 - 0.1090
Volume371,400
Avg. Volume2,481,750
Market Cap61M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Gordian Surgical Raises $3 Million for Commercialization of Its Laparoscopic Closure System
    PR Newswire

    Gordian Surgical Raises $3 Million for Commercialization of Its Laparoscopic Closure System

    Investors included a group of Chinese investors, American physicians, and current shareholders. Gordian Surgical is a commercial-stage medical device company with growing international sales of its innovative TroClose 1200 access-closure system for laparoscopic surgery.

  • Fidmi Medical Receives FDA Regulatory Clearance for Low-profile Enteral Feeding Device
    PR Newswire

    Fidmi Medical Receives FDA Regulatory Clearance for Low-profile Enteral Feeding Device

    CAESAREA, Israel , Oct. 16, 2019 /PRNewswire/ -- Fidmi Medical Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced today that it received ...

  • Gordian Surgical's Closure System Used in Panama by PanaFarma
    PR Newswire

    Gordian Surgical's Closure System Used in Panama by PanaFarma

    PanaFarma wins tender to supply social security hospitals with closure system for two years. ("Trendlines") (42T.SI) (TRNLY), announced today that its exclusive distributor in Panama - PanaFarma - has won the tender to supply Panama's social security hospitals with the TroClose™1200 access-closure system for a two-year period. As a commercial-stage medical device company with growing international sales of its innovative TroClose 1200 access-closure system for laparoscopic surgery, this translates to the sale of a few thousand products to Panama.

  • PR Newswire

    FruitSpec Closes $4 Million Investment From AgVentures & Hubei Forbon Technology for Its Yield Estimation Solution

    MISGAV, Israel, Sept. 24, 2019 /PRNewswire/ -- FruitSpec, a portfolio company of The Trendlines Group Ltd. (42T.SI) (TRNLY), is pleased to announce that it has completed an investment round of $4 million. Investors included AgVentures, a South African agtech investment company and Hubei Forbon Technology Co. Ltd., China. Inaccurate fruit yield estimation from an early stage (especially in green fruit) remains a key problem in the food chain.

  • OrthoSpin Receives FDA Regulatory Clearance
    PR Newswire

    OrthoSpin Receives FDA Regulatory Clearance

    MISGAV, Israel , Sept. 18, 2019 /PRNewswire/ -- OrthoSpin Ltd. a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced today that it received regulatory ...

  • PR Newswire

    MetoMotion Receives $1.5 Million Investment From Netherlands-based Strategic Partner for Its Greenhouse Robotic Worker (GRoW)

    MISGAV, Israel, July 31, 2019 /PRNewswire/ -- MetoMotion, a portfolio company of The Trendlines Group Ltd. (42T.SI) (TRNLY), announced that it has completed an investment round of $1.5 million, which was led by a leading Netherlands-based company in the greenhouse industry. Greenhouses today face two critical problems, both of which contribute to economic damage: (1) increasing labor shortages and (2) a lack of skilled labor. With labor costs accounting for up to 50% of total greenhouse production costs, growers are looking to technology to solve the labor crunch.

  • PR Newswire

    The Trendlines Group Receives SGD10.88 Million (USD8 million) Investment

    MISGAV, Israel, July 22, 2019 /PRNewswire/ -- The Trendlines Group Ltd. ("Trendlines") (42T.SI) (TRNLY) today announced that it has signed a Subscription Agreement with Librae Holdings Limited ("LH"), for an SGD10.88 million (USD8 million) investment. London-based discretionary beneficiary to the trust that is sole shareholder of LH, Mr. Vincent Tchenguiz, is best known for his multi-billion-pound real estate portfolio. In the past three years, he has diversified his investments with increased focus on biotechnology and planet related technologies and built a USD350 million technology venture capital portfolio managed by a strong tech investment team1.

  • CNW Group

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • PR Newswire

    Bayer Trendlines Ag Innovation Fund to Co-invest With Trendlines in New Company

    MISGAV, Israel and MONHEIM, Germany, July 10, 2019 /PRNewswire/ -- The Bayer Trendlines Ag Innovation Fund, set up by Bayer CropScience LLC ("Bayer") and The Trendlines Group Ltd. ("Trendlines") (42T.SI) (TRNLY), announced that it established EcoPhage Ltd. ("EcoPhage"), a new company focused on discovering and developing environmentally friendly products for disease control in agriculture. The Company will leverage a disruptive technology for using bacteriophages, viruses that attack bacteria, for crop protection.

  • PR Newswire

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • PR Newswire

    The Trendlines Group Ltd. to Webcast Live at VirtualInvestorConferences.com July 11th

    Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com MISGAV, Israel , July 9, 2019 ...

  • ProArc Medical Awarded $2.2 Million European Union Grant
    PR Newswire

    ProArc Medical Awarded $2.2 Million European Union Grant

    TEL AVIV, Israel, July 2, 2019 /PRNewswire/ --  ProArc Medical ("ProArc"),  announced that it received a $2.2 million grant from the prestigious Horizon 2020 program as a part of the  European ...

  • Limaca Medical Initiates First-in-Human Study of Biopsy Device for Improved Tumor Diagnosis
    PR Newswire

    Limaca Medical Initiates First-in-Human Study of Biopsy Device for Improved Tumor Diagnosis

    MISGAV, Israel , May 16, 2019 /PRNewswire/ --  Limaca Medical Ltd. ("Limaca"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced the ...

  • BioFishency Raises $2.4 Million for its Water Treatment Systems for Aquaculture
    PR Newswire

    BioFishency Raises $2.4 Million for its Water Treatment Systems for Aquaculture

    MISGAV, Israel, March 27, 2019 /PRNewswire/ -- BioFishency Ltd. ("BioFishency" or "the Company"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (42T.SI) (TRNLY), announced that it has completed an investment round of $2.4 million. The primary investors in the round were a private investor from China, Aqua-Spark, a global investment fund based in the Netherlands, and The Trendlines Group. BioFishency is an aquaculture solutions provider focused on dramatically increasing growers' productivity and sustainability through its innovative technologies and extensive knowhow.

  • BioFishency Raises $2.4 Million for Its Water Treatment Systems for Aquaculture
    PR Newswire

    BioFishency Raises $2.4 Million for Its Water Treatment Systems for Aquaculture

    MISGAV, Israel, March 27, 2019 /PRNewswire/ -- BioFishency Ltd. ("BioFishency" or "the Company"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (42T.SI) (TRNLY), announced that it has completed an investment round of $2.4 million. The primary investors in the round were a private investor from China, Aqua-Spark, a global investment fund based in the Netherlands, and The Trendlines Group. BioFishency is an aquaculture solutions provider focused on dramatically increasing growers' productivity and sustainability through its innovative technologies and extensive knowhow.

  • PR Newswire

    Omeq Medical Penetrates Epidural Market in China Through US$3 Million Funding and Commercialization Agreement With Pharos Medical

    Omeq Medical Ltd. ("Omeq"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (42T.SI) (TRNLY), announced today that it has signed an investment and commercialization agreement for its smart epidural device with Pharos Medical ("Pharos"), a Shanghai-based manufacturer and distributor of medical devices. Omeq has developed a single-use, smart epidural device for safe, accurate epidural injections to thwart inaccurate needle placement - estimated at up to 30% of initial injections.